Vasculitis Clinical Trial
Official title:
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
The purpose of this study is to assess the safety, tolerance, and immunologic effects of interleukin-10 (IL-10), in patients with Wegener's granulomatosis. A secondary objective is to determine if IL-10 demonstrates sufficient anti-inflammatory activity in the treatment of Wegener's granulomatosis to warrant further study in a larger trial. In this study, IL-10 will be given either alone or in combination with standard therapeutic agents, usually consisting of cyclophosphamide, methotrexate, and/or prednisone. Patients will be eligible to receive IL-10 when there is evidence of active disease. IL-10 will be administered by subcutaneous injection at a dose of 4 µ (Micro)g/kg/day for 28 days.
The purpose of the study is to assess the safety, tolerance, and immunologic effects of interleukin-10 (IL-10), in patients with Wegener's granulomatosis. A secondary objective is to determine if IL-10 demonstrates sufficient anti-inflammatory activity in the treatment of Wegener's granulomatosis to warrant further study in a larger trial. In this study, IL-10 will be given either alone or in combination with standard therapeutic agents, usually consisting of cyclophosphamide, methotrexate, and/or prednisone. Patients will be eligible to receive IL-10 when there is evidence of active disease. IL-10 will be administered by subcutaneous injection at a dose of 4 µ (Micro)g/kg/day for 28 days. ;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02498808 -
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?
|
N/A | |
| Completed |
NCT01363388 -
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
|
Phase 2 | |
| Completed |
NCT00004357 -
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
|
Phase 2 | |
| Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT01947465 -
Immunogenicity and Safety of Vaccinations in Immunocompromised Persons
|
N/A | |
| Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
| Completed |
NCT03693586 -
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
|
||
| Completed |
NCT05604482 -
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
|
N/A | |
| Completed |
NCT03765424 -
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT05383339 -
Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
|
||
| Active, not recruiting |
NCT03755245 -
Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis
|
N/A | |
| Recruiting |
NCT05565885 -
Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
|
||
| Recruiting |
NCT02593565 -
Vasculitis Pregnancy Registry
|
||
| Recruiting |
NCT02856243 -
Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis
|
N/A | |
| Recruiting |
NCT05628948 -
Vascular Lab Resource (VLR) Biorepository
|
||
| Active, not recruiting |
NCT03692416 -
The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children
|
Phase 3 | |
| Completed |
NCT05115370 -
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
|
||
| Terminated |
NCT03937856 -
Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases
|
N/A |